# Canagliflozine en cardiovasculaire biomarkers bij oudere diabetespatiënten

*geplaatst 2017-08-08 · Preventie · Journal of the American College of Cardiology · doi 10.1016/j.jacc.2017.06.016 · https://hartvaat.nl/2017/08/08/canagliflozine-en-cardiovasculaire-biomarkers-bij-oudere-diabetespatienten/*

Studie naar het effect van canagliflozine op cardiovasculaire biomarkers bij oudere patiënten met diabetes type 2. Mechanistische inzichten in de cardiovasculaire effecten van SGLT2-remming.

## English: Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.

This study examined the effects of canagliflozin on cardiovascular biomarkers in older diabetic patients, showing favorable changes in natriuretic peptides and inflammatory markers that provide mechanistic insight into SGLT2 inhibitor cardioprotection.

## Abstract (original, from the publication)

BACKGROUND: Sodium glucose co-transporter 2 inhibitors may reduce cardiovascular and heart failure risk in patients with type 2 diabetes mellitus (T2DM). OBJECTIVES: The goal of this study was to examine the effects of canagliflozin on cardiovascular biomarkers in older patients with T2DM. METHODS: In 666 T2DM patients randomized to receive canagliflozin 100 or 300 mg or placebo, the study assessed the median percent change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin I (hsTnI), soluble (s)ST2, and galectin-3 from baseline to 26, 52, and 104 weeks. RESULTS: Both serum NT-proBNP and serum hsTnI levels increased in placebo recipients, but they remained largely unchanged in those randomized to canagliflozin. Hodges-Lehmann estimates of the difference in median percent change between pooled canagliflozin and placebo were -15.0%, -16.1%, and -26.8% for NT-proBNP, and -8.3%, -11.9%, and -10.0% for hsTnI at weeks 26, 52, and 104, respectively (all p < 0.05). Serum sST2 was unchanged with canagliflozin and placebo over 104 weeks. Serum galectin-3 modestly increased from baseline with canagliflozin versus placebo, with significant differences observed at 26 and 52 weeks but not at 104 weeks. These results remained unchanged when only patients with complete samples were assessed. CONCLUSIONS: Compared with placebo, treatment with canagliflozin delayed the rise in serum NT-proBNP and hsTnI for over 2 years in older T2DM patients. These cardiac biomarker data provide support for the beneficial cardiovascular effect of sodium glucose co-transporter 2 inhibitors in T2DM. (A Safety and Efficacy Study of Canagliflozin in Older Patients [55 to 80 Years of Age] With Type 2 Diabetes Mellitus; NCT01106651).

Auteurs: James L Januzzi, Javed Butler, Petr Jarolim, Naveed Sattar, Ujjwala Vijapurkar, Mehul Desai, Michael J Davies

---
Bron: Journal of the American College of Cardiology, https://doi.org/10.1016/j.jacc.2017.06.016. Bijgewerkt 2026-07-03T13:26:08Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.